Development and clinical application of bioelectrical impedance analysis method for body composition assessment
- PMID: 39350475
- DOI: 10.1111/obr.13844
Development and clinical application of bioelectrical impedance analysis method for body composition assessment
Abstract
Obesity, which is characterized by excessive body fat, increases the risk of chronic diseases, such as type 2 diabetes, cardiovascular diseases, and certain cancers. Sarcopenia, a decline in muscle mass, is also associated with many chronic disorders and is therefore a major concern in aging populations. Body composition analysis is important in the evaluation of obesity and sarcopenia because it provides information about the distribution of body fat and muscle mass. It is also useful for monitoring nutritional status, disease severity, and the effectiveness of interventions, such as exercise, diet, and drugs, and thus helps assess overall health and longevity. Computed tomography, magnetic resonance imaging, and dual-energy X-ray absorptiometry are commonly used for this purpose. However, they have limitations, such as high cost, long measurement time, and radiation exposure. Instead, bioelectrical impedance analysis (BIA), which was introduced several decades ago and has undergone significant technological advancements, can be used. It is easily accessible, affordable, and importantly, poses no radiation risk, making it suitable for use in hospitals, fitness centers, and even at home. Herein, we review the recent technological developments and clinical applications of BIA to provide an updated understanding of BIA technology and its strengths and limitations.
Keywords: body composition; fat; impedance; muscle; obesity; sarcopenia.
© 2024 World Obesity Federation.
References
REFERENCES
-
- Lee Y, Shin H, Vassy JL, et al. Comparison of regional body composition and its relation with cardiometabolic risk between BMI‐matched young and old subjects. Atherosclerosis. 2012;224(1):258‐265. doi:10.1016/j.atherosclerosis.2012.07.013
-
- Baumgartner RN, Heymsfield SB, Roche AF. Human body composition and the epidemiology of chronic disease. Obes Res. 1995;3(1):73‐95. doi:10.1002/j.1550‐8528.1995.tb00124.x
-
- Stefan N. Causes, consequences, and treatment of metabolically unhealthy fat distribution. Lancet Diabetes Endocrinol. 2020;8(7):616‐627. doi:10.1016/S2213‐8587(20)30110‐8
-
- Amati F, Pennant M, Azuma K, et al. Lower thigh subcutaneous and higher visceral abdominal adipose tissue content both contribute to insulin resistance. Obesity (Silver Spring). 2012;20(5):1115‐1117. doi:10.1038/oby.2011.401
-
- Kadowaki T, Isendahl J, Khalid U, et al. Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double‐blind, double‐dummy, placebo‐controlled, phase 3a trial. Lancet Diabetes Endocrinol. 2022;10(3):193‐206. doi:10.1016/S2213‐8587(22)00008‐0
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
